Monthly Archives: October 2012

How does the NBI perform in the last quarter of the year?

YTD-10-08-2012

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months of the year, or underperform? The NBI tends to be up in the 4th quarter, but a lot of that has to do with the overall market, not the biotechs. Here are the returns for the last quarter of the year for the last 20 years: (source: Factset) When looking directly at overall performance, biotech and the broader market have had good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

deborah

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

#BIF2012 Company Snapshot: Chimerix

Chimerix

Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

Is the early-stage IPO making a comeback?

Yesterday was the NASDAQ debut for preclinical-stage biotech Regulus (RGLS). The microRNA platform company is working in multiple therapeutic areas and planning to reach the clinic in 2014. Since the start of the 2009 post-market crash window for biotech IPOs, there have been only two preclinical biotech companies to make it to the public stage. Back in January, we saw Verastem (VSTM), at only 1.5 years of age, make it to the NASDAQ and raise Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

“Approval of Foods from Genetically Modified Animals is Unjustifiably Slow”

salmon

The Los Angeles Times reported on concerns within the U.S. animal biotech industry and the chilling effect that will result if the government continues to turn its back on technologies in the pipeline. If the political process doesn’t allow the science-based regulatory process to work, we risk losing out on the benefits of this dynamic industry to other countries that are encouraging research and investment in this area. Rosie Mestel of the Los Angeles Times Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , ,